Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;27(1):78-88.
doi: 10.1007/s11307-024-01969-z. Epub 2024 Dec 9.

Preclinical and Clinical-Scale Magnetic Particle Imaging of Natural Killer Cells: in vitro and ex vivo Demonstration of Cellular Sensitivity, Resolution, and Quantification

Olivia C Sehl  1 , Yanwen Yang  2 , Ariana R Anjier  2 , Dmitry Nevozhay  3 , Donghang Cheng  2 , Kelvin Guo  4 , Benjamin Fellows  4 , Abdul Rahman Mohtasebzadeh  4 , Erica E Mason  4 , Toby Sanders  4 , Petrina Kim  4 , David Trease  4 , Dimpy Koul  5 , Patrick W Goodwill  4 , Konstantin Sokolov  3 , Max Wintermark  5 , Nancy Gordon  2 , Joan M Greve  4 , Vidya Gopalakrishnan  6   7   8   9
Affiliations

Preclinical and Clinical-Scale Magnetic Particle Imaging of Natural Killer Cells: in vitro and ex vivo Demonstration of Cellular Sensitivity, Resolution, and Quantification

Olivia C Sehl et al. Mol Imaging Biol. 2025 Feb.

Abstract

Purpose: Clinical adoption of NK cell immunotherapy is underway for medulloblastoma and osteosarcoma, however there is currently little feedback on cell fate after administration. We propose magnetic particle imaging (MPI) may have applications for the quantitative detection of NK cells.

Procedures: Human-derived NK-92 cells were labeled by co-incubation with iron oxide nanoparticles (VivoTrax™) for 24 h then excess nanoparticles were washed with centrifugation. Cytolytic activity of labeled versus unlabeled NK-92 cells was assessed after 4 h of co-incubation with medulloblastoma cells (DAOY) or osteosarcoma cells (LM7 or OS17). Labeled NK-92 cells at two different doses (0.5 or 1 × 106) were administered to excised mouse brains (cerebellum), fibulas, and lungs then imaged by 3D preclinical MPI (MOMENTUM™) for detection relative to fiducial markers. NK-92 cells were also imaged by clinical-scale MPI under development at Magnetic Insight Inc.

Results: NK-92 cells were labeled with an average of 3.17 pg Fe/cell with no measurable effects on cell viability or cytolytic activity against 3 tumor cell lines. MPI signal was directly quantitative with the number of labeled NK-92 cells, with preclinical limit of detection of 3.1 × 104 cells on MOMENTUM imager. Labeled NK-92 cells could be accurately localized in mouse brains, fibulas, and lungs within < 1 mm of stereotactic injection coordinates with preclinical scanner. Feasibility for detection on a clinical-scale MPI scanner was demonstrated using 4 × 107 labeled NK-92 cells, which is in the range of NK cell doses administered in our previous clinical trial.

Conclusion: MPI can provide sensitive, quantitative, and accurate spatial information on NK cells soon after delivery, showing initial promise to address a significant unmet clinical need to track NK cell fate in patients.

Keywords: Immunotherapy; Iron; Magnetic particle imaging; Medulloblastoma; NK cells; Nanoparticle; Osteosarcoma.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical Approval: This study followed all applicable institutional and/or national guidelines for the care and use of animals. Conflict of interest: Authors O.C.S., K.G., B.F., A.R.M., E.E.M., T.S., P.K., D.T., P.W.G., and J.M.G. report relationship with Magnetic Insight Inc. that includes employment and stock ownership.

Similar articles

See all similar articles

Cited by

  • Medulloblastoma: biology and immunotherapy.
    Poggi A, Reggiani F, Azevedo HS, Raffaghello L, Pereira RC. Poggi A, et al. Front Immunol. 2025 Jul 3;16:1602930. doi: 10.3389/fimmu.2025.1602930. eCollection 2025. Front Immunol. 2025. PMID: 40677711 Free PMC article. Review.

References

    1. Toffoli EC, Sheikhi A, Höppner YD et al. (2021) Natural killer cells and anti-cancer therapies: reciprocal effects on Immune function and therapeutic response. Cancers (Basel) 13:711. - PMC - PubMed
    1. Shimasaki N, Jain A, Campana D (2020) NK cells for cancer immunotherapy. Nat Rev Drug Discov 19:200–218 - PubMed
    1. Valipour B, Velaei K, Abedelahi A et al. (2019) NK cells: an attractive candidate for cancer therapy. J Cell Physiol 234(11):19352–19365 - PubMed
    1. Buddingh EP, Schilham MW, Ruslan SEN et al. (2011) Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 60:575–586 - PMC - PubMed
    1. Chang TC, Carter RA, Li Y et al. (2017) The neoepitope landscape in pediatric cancers. Genome Med 9:1–12 - PMC - PubMed

Substances

LinkOut - more resources